Abstract
The clinical impact of the association between oral contraceptive (OC) use and breast cancer risk is important given that OCs are the most commonly prescribed contraceptive agent and that more than a quarter of a million women are diagnosed as having breast cancer in the United States annually. Substantial changes to OC formulations have been made during the past decade, and this review focuses on recent OC trends and risks and benefits. We also have a better understanding of how estrogen affects breast carcinogenesis; research on this topic is ongoing and has the goal of decreasing breast cancer incidence and mortality.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 86-91 |
| Number of pages | 6 |
| Journal | Mayo Clinic Proceedings |
| Volume | 83 |
| Issue number | 1 |
| DOIs | |
| State | Published - 2008 |
Fingerprint
ASJC Scopus subject areas
- Medicine(all)
Cite this
Oral contraceptive use and the risk of breast cancer. / Casey, Petra Marcela; Cerhan, James R; Pruthi, Sandhya.
In: Mayo Clinic Proceedings, Vol. 83, No. 1, 2008, p. 86-91.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Oral contraceptive use and the risk of breast cancer
AU - Casey, Petra Marcela
AU - Cerhan, James R
AU - Pruthi, Sandhya
PY - 2008
Y1 - 2008
N2 - The clinical impact of the association between oral contraceptive (OC) use and breast cancer risk is important given that OCs are the most commonly prescribed contraceptive agent and that more than a quarter of a million women are diagnosed as having breast cancer in the United States annually. Substantial changes to OC formulations have been made during the past decade, and this review focuses on recent OC trends and risks and benefits. We also have a better understanding of how estrogen affects breast carcinogenesis; research on this topic is ongoing and has the goal of decreasing breast cancer incidence and mortality.
AB - The clinical impact of the association between oral contraceptive (OC) use and breast cancer risk is important given that OCs are the most commonly prescribed contraceptive agent and that more than a quarter of a million women are diagnosed as having breast cancer in the United States annually. Substantial changes to OC formulations have been made during the past decade, and this review focuses on recent OC trends and risks and benefits. We also have a better understanding of how estrogen affects breast carcinogenesis; research on this topic is ongoing and has the goal of decreasing breast cancer incidence and mortality.
UR - http://www.scopus.com/inward/record.url?scp=37549017282&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=37549017282&partnerID=8YFLogxK
U2 - 10.4065/83.1.86
DO - 10.4065/83.1.86
M3 - Article
C2 - 18174010
AN - SCOPUS:37549017282
VL - 83
SP - 86
EP - 91
JO - Mayo Clinic Proceedings
JF - Mayo Clinic Proceedings
SN - 0025-6196
IS - 1
ER -